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Abstract
Background: Topoisomerase I (TOP1) is a nuclear enzyme that catalyzes the relaxation of supercoiled DNA during
DNA replication and transcription. TOP1 is the molecular target of camptothecin and related drugs such as
irinotecan and SN38 (irinotecan’s active metabolite). Irinotecan is widely used as an anti-cancer agent in the
treatment of metastatic colon cancer. However, its efficacy is often limited by the development of resistance.
Methods: We previously established several SN38 resistant HCT116-derived clones to study the mechanisms
underlying resistance to SN38. Here, we investigated whether resistance to SN38 in these cell lines could be linked
to the presence of TOP1 mutations and changes in its expression and activity. Functional analyses were performed
on these cell lines challenged with SN38 and we specifically monitored the double strands breaks with gH2AX
staining and replication activity with molecular combing.
Results: In SN38 resistant HCT116 clones we identified three new TOP1 mutations, which are located in the core
subdomain III (p.R621H and p.L617I) and in the linker domain (p.E710G) and are packed together at the interface
between these two domains. The presence of these TOP1 mutations in SN38 resistant HCT116 cells did not modify
TOP1 expression or intrinsic activity. Conversely, following challenge with SN38, we observed a decrease of TOP1-
DNA cleavage complexes and a reduction in double-stranded break formation). In addition, we showed that SN38
resistant HCT116 cells present a strong decrease in the SN38-dependent asymmetry of replication forks that is
characteristic of SN38 sensitive HCT116 cells.
Conclusions: These results indicate that the TOP1 mutations are involved in the development of SN38 resistance.
We hypothesize that p.L617, p.R621 and p.E710 TOP1 residues are important for the functionality of the linker and
that mutation of one of these residues is sufficient to alter or modulate its flexibility. Consequently, linker
fluctuations could have an impact on SN38 binding by reducing the enzyme affinity for the drug.
Background
Irinotecan (CPT-11), a semi-synthetic water-soluble
derivative of camptothecin, is widely used for the treat-
ment of metastatic colon cancer in first- and second-
line therapies [1]. CPT-11 is a pro-drug which is con-
verted by carboxylesterases into the active form SN38.
Like other camptothecin derivatives, SN38 exerts its
cytotoxic activity through inhibition of Topoisomerase 1
(TOP1). Human TOP1 is a nuclear enzyme responsible
for the relaxation of supercoiled DNA, which is needed
for DNA replication, transcription and chromatin con-
densation [2,3]. TOP1 first introduces a nick in one
strand of duplex DNA and then religates the TOP1-
linked DNA break. SN38 interferes with TOP1 activity
by inhibiting the religation step and induces the forma-
tion of stable covalent ternary complexes at DNA break-
age points [4]. As a consequence, collision with the
replication machinery produces double strand breaks at
the replication fork [5].
The most frequently reported cellular mechanisms of
resistance to CPT-11 include reduced intracellular drug
accumulation (mediated by ABC transporters) [6,7],
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tative and qualitative alterations of the TOP1 protein
[9-11] and alterations in the cellular response to ternary
complex formation that ultimately lead to repair of
DNA damage or cell death [3,12].
TOP1 mutations that confer resistance to camptothe-
cin derivatives have been identified in mammalian cells
and yeast [13-16]. Most of them are located close to the
active site of the enzyme or clustered in two regions of
the core domain [17]. Recently, Benedetti and colleagues
showed that the p.A653P mutation limits the flexibility
of the linker domain [18]. Studies of clinical specimens
are needed to determine whether such mutations can be
found also in patients and are involved in chemotherapy
resistance. Among the few studies that have investigated
t h ep r e s e n c eo fTOP1 mutations in clinical samples
[19-21], only one reported two point mutations (p.
W736X and p.G737S on the same allele) in tumor tis-
sues from a patient treated with CPT-11 [21]. However,
this result has never been confirmed.
We have previously established SN38 resistant clones
from the human colon carcinoma cell line HCT116 to
investigate the mechanisms that lead to resistance to
SN38 [7,22]. In this study, we identified three new TOP1
mutations in these clones. Moreover, we show that, fol-
lowing treatment with SN38, DNA cleavage complexes
and DNA double strand break formation are reduced in
SN38 resistant cells as well as the SN38-induced asym-
metry of the replication fork that is typical of SN38 sensi-
tive cells. Finally, the localization of these new TOP1
mutations suggests that they could influence the linker
flexibility and possibly alter TOP1/SN38 interaction.
Methods
Cell lines
The HCT116 colon adenocarcinoma cell line was pur-
chased from ATCC (Manassas, VA, USA). Cells were
grown in RPMI 1640 supplemented with 10% fetal calf
s e r u m( F C S )a n d2m ML - g l u t a m i n ea t3 7 ° Cu n d e ra
humidified atmosphere with 5% CO2, and passaged by
trypsinization. The HCT116-s and HCT116-SN6,
HCT116-A2, HCT116-SN50, HCT116-C8 and HCT116-
G7 clones were obtained as previously described [7].
Briefly, parental HCT116 cells were first cloned to obtain
a reference SN38 sensitive clone, referred to as HCT116-
s. This sensitive clone was then continuously exposed to
SN38 with stepwise increased concentrations ranging
from 1 nM to 15 nM over a period of approximately 8
months. The cell population growing in 10 nM SN38 was
cloned to obtain the HCT116-SN6 and HCT1116-A2
clones, and the cloning of the population growing in 15
nM SN38 gave us the HCT116-SN50, HCT116-C8 and
HCT116-G7 clones (Figure 1A). Drug-selected clones
were maintained in the appropriate concentration of
SN38. All the cell lines were cultured in drug-free med-
ium at least 5 days prior to any experiment.The
HCT116-SN6 and HCT116-SN50 cells have been pre-
viously described and partially characterized [7,22].
Drug sensitivity assay and calculation of the doubling
time
Cell growth inhibition and cell viability after SN38 treat-
ment were assessed using the Sulforhodamine B (SRB)
and the clonogenic assays as previously described [22].
To calculate the doubling time (DT), cells (15 ×10
4)
were seeded in seven identical 25 cm
2 flasks for each
counting experiment. Then, every 24 hours the viable
cells of one flask were counted with a hemocytometer
after Trypan blue staining. DT was calculated during
exponential growing phase as following: DT = h*ln(2)/ln
(c2/c1); h = time point in hours; c1 and c2 = cell con-
centration at the beginning and at the end of h.
Immunoblotting
Whole cell lysates were prepared as previously described
[22]. Proteins from the extracts (10
5 cells per lane) were
electrophoretically separated on 10% SDS-PAGE, then
electro-transferred onto polyvynilidene difluoride mem-
branes (Amersham Biosciences, Buckinghamshire, UK).
Membranes were incubated with the appropriate pri-
mary antibody: polyclonal anti-Top1 [23], anti-ABCG2
[7] anti-GAPDH (clone 6C5) antibody from Millipore
(Billerica, MA, USA),. Secondary antibodies were peroxi-
dase-conjugated anti-mouse (Sigma-Aldrich, St. Louis,
MO, USA) and anti-rabbit anti-sera (Sigma-Aldrich,
Saint-Louis, MO, USA).
Nucleotide sequencing
Total RNA was isolated from sensitive and resistant
HCT116 cells using the RNeasy Mini Kit (Qiagen, CA,
USA), followed by synthesis of first-strand cDNA. TOP1
cDNA was amplified by PCR in 6 overlapping frag-
ments, using the following primers:
(1) 5’-CTCAGCCGTTTCTGGAGTCT-3’ and 5’-TCA
GCATCATCCTCATCTCG;
(2) 5’-CGAAAAGAGGAAAAGGTTC-3’ and 5’-GGG
CTCAGCTTCATGACTTT;
(3) 5’-CCACCATATGAGCCTCTTCC-3’ and 5’-CCT
TGTTATCATGCCGGACT;
(4) 5’-AGAGCCTCCTGGACTTTTCC-3’ and 5’-GAC
CATCCAACTCTGGGTGT-3’;
(5) 5’- TTCGTGTGGAGCACATCAAT-3’ and 5’-GAC
CTTGGCATCAGCCTTAG-3’;
(6) 5’-CGAGCTGTTGCAATTCTTTG-3’ and 5’-ACC
ACACTGTTCCTCTTCAC-3’.
Purified PCR products were then sequenced using the
same sense primers by the dideoxynucleotide method
using the MWG Biotech sequencing service.
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The TOP1 region that contains the p.R621H and p.
E710G mutations was PCR amplified using the 5’-
AGAGCCTCCTGGACTTTTCC-3’ and 5’-A C C A -
CACTGTTCCTCTTCAC-3 primers from HCT116-SN6
cDNA. The amplicon was digested with HindIII and
HaeI I Ia n dt h e nc l o n e di nHindIII-EcoRVd i g e s t e da n d
dephosphorylated pcDNA3 plasmid. Ligation was trans-
formed in C-Max5aF’ cells that were grown on LB with
100 μg/ml ampicillin for 16 h at 37°C. Transformants
were selected by PCR screening; PCR products were
then purified and sequenced.
High Resolution Melting (HRM) analysis
Primers were designed using the LightCycler Probe
Design Software 2.0 and were: 5’-GATGAGAACATCC-
CAGCGA-3’ and 5’-GCAAGTTCATCATAGACTTCT-
CAA-3’ for the detection of the p.R621H mutation; 5’-
CAGTTGATGAAGCTGGAAGT-3’ and 5’-CTGTGA
TCCTAGGGTCCAGAT-3’ for the detection of the p.
E710G mutation. HRM analysis of cDNA samples or
PCR products (amplification of the TOP1 region that
contains the p.R621H and p.E710G mutations, as
described in the previous paragraph “DNA cloning”)
were carried out in duplicate using the LightCycler 480
System (Roche, Indianapolis, IN, USA). The reaction
mixture in a 10 μl final volume consisted of 0.2 μMo f
each primer, 5 μL of master mix, which contained the
Taq polymerase, nucleotides and the ResoLight dye
(Roche, Indianapolis, IN, USA), 3 mM of MgCl2 and 10
ng of cDNA. The PCR program consisted of an initial
denaturation-activation step at 95°C for 10 min followed
by 40 cycles (denaturation at 95°C for 15 s, annealing at
58°C 15 s and elongation at 72°C for 15 s with reading
of the fluorescence; acquisition mode: single). The melt-
ing program included three steps: denaturation at 95°C
for 1 min, renaturation at 40°C for 1 min to encourage
heteroduplex formation and melting over the desired
A
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HCT116-A2 10 106 ± 16.5 (56) 25.0
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HCT116-G7 15 28 ± 7.7 (15) 42.1
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Figure 1 Generation and characterization of SN38-resistant HCT116 cells: A) Schematic representation of the production of SN38-resistant
HCT116 cell clones. B) Drug sensitivity and growth rate of the HCT116 clones: IC50 values were determined using the Sulforhodamine B assay;
the resistance factor (RF; in between brackets) was determined by dividing the IC50 value of each resistant clone by that of the sensitive clone
HCT116-s. Data represent the mean ± SD of at least 3 independent experiments. Doubling time was calculated during the exponential growing
phase as following: doubling time (in hours) = h*ln(2)/ln(c2/c1); c1 and c2 are the cell concentration at the beginning and the end of the
chosen period of time C) TOP1 and ABCG2 protein expression by western blotting. Equal loading is shown by GAPDH. Values below the blot
represent relative quantization of TOP1.
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obtain the HRM curve data at a rate of 25 acquisitions
per 1°C. The melting curve analysis carried out by the
Gene-Scanning Software comprises three steps: normali-
zation of the melting curves by equalizing the initial
fluorescence and the remaining fluorescence after DNA
dissociation to 100% and 0%, respectively; shifting of the
temperature axis of the normalized melting curves to
the point where the entire double-stranded DNA is
completely denatured; and finally, analysis of the differ-
ences in the melting-curve shapes by subtracting the
curves of wild type and mutated DNAs (difference plot).
Immunocomplex of enzyme (ICE) bioassay
Covalent TOP1-DNA adducts were isolated using the
ICE bioassay according to a previously published proce-
dure [24]. Briefly, 10
6 cells were lysed with 1% sarcosyl
and layered on step gradients containing CsCl solutions
(2 mL each) of the following densities: 1.82, 1.72, 1.50,
and 1.45. Tubes were centrifuged at 165,000 × g in a
Beckman SW40 rotor for 17 h at 20°C and 0.5 ml frac-
tions were collected from the bottom of the tubes.
DNA-containing fractions were pooled, normalized for
DNA concentration, diluted with an equal volume of 25
mM NaPO4 buffer (pH 6.5) and applied to Immobilon-
P membranes with a slot-blot vacuum manifold. TOP1-
DNA adducts were visualized by immunostaining using
the polyclonal anti-TOP1 antibody from Abcam (ab-
3825, Cambridge, MA, USA).
Phosphorylated H2AX quantification by flow cytometry
analysis
Cells were seeded in 25 cm
2 flasks (2 × 10
5 cells/flask).
After a 48-hour rest, cells were incubated with 0.5 μM
SN38 for 20 hours. One million cells were pelleted,
fixed and permeabilized according to the H2AX Phos-
phorylation Assay Kit (Upstate Biotechnology, Lake Pla-
cid, NY, USA) and incubated with the anti-phospho-
Histone H2A.X FITC conjugated antibody to detect His-
tone H2A.X phosphorylation at Serine 139. Analyses
were done using an Epics Coulter flow cytometer (Beck-
man, Ramsey, MN, USA) and results quantified with the
Expo 32 analysis software (Coulter, Ramsey, MN, USA).
Phosphorylated H2AX detection by fluorescence
microscopy
Cells growing on chamber slides were treated with 0.5 μM
SN38 for 20 hours. Slides were fixed with 4% paraformald-
hehyde/PBS at room temperature for 10 min, permeabi-
lized with 0.1% Triton X100/PBS at room temperature for
10 min and blocked with PBS containing 5% BSA at 37°C
for 30 min. Slides were incubated with 1/100 diluted
mouse anti-phospho-histone H2AX (ser139) FITC conju-
gated antibody (Upstate Biotechnology, Lake Placid, NY,
USA) and DAPI was used to stain the nucleus. Stained
cells were mounted in Moviol, and images were recorded
using a 63XNA objective on a Leica inverted microscope.
DNA combing
DNA combing was performed as previously described
[25,26]. DNA fibers from the different HCT116 clones
were extracted in agarose plugs immediately after label-
ing and were stretched on silanized coverslips. In fork
recovery experiments, CldU and IdU were detected with
the anti-BrdU antibodies BU1/75 (AbCys, Paris, France)
and BD44 (Becton Dickinson, Franklin Lakes, NJ, USA),
respectively. DNA fibers were analyzed on a Leica
DM6000B microscope equipped with a CoolSNAP HQ
CCD camera (Roper Scientifics, Sarasota, Florida, USA)
and a 40x objective. Image acquisition was performed
with MetaMorph (Roper Scientifics, Sarasota, Florida,
USA). Representative images of DNA fibers were
assembled from different fields of view and processed as
described [27] with Adobe Photoshop.
Cell cycle distribution
To determine the cell cycle distribution, SN38 sensitive
and resistant, exponentially growing HCT116 cells were
plated (1 × 10
5 cells) in 6-well plates and 24 hours later
cells were exposed to 20 nM SN38. After 24 hours of
treatment, untreated and treated cells were washed in
ice cold PBS, fixed in 70% ethanol and labeled with 40
μg/ml propidium iodide (Sigma-Aldrich, Saint-Louis,
MO, USA) containing 100 μg/ml RNase A (Sigma-
Aldrich, Saint-Louis, MO, USA) at 37°C for 1.5 hours.
Cell cycle distribution was then determined with a
FACScan fluorescence-activated cell sorter (Becton
Dickinson, Franklin Lakes, MD, USA) using the FL-2
channel. Cells were gated on a dot plot that displayed
DNA pulse-width versus DNA-pulse area to exclude
aggregated cells. Cell cycle distributions were illustrated
using the WinMDI2.8 histogram analysis software
(Phoenix Flow Systems, San Diego, CA, USA) and quan-
tified using Multicycle (DNA-cell cycle analysis software
distributed by Phoenix Flow Systems, San Diego, CA,
USA).
Colorectal cancer patients
Normal and cancer colon samples and hepatic metas-
tases were obtained from 45 advanced colorectal cancer
patients with synchronous hepatic metastases who were
followed at the CRLC Val d’Aurelle, Montpellier, France.
The clinical features of these patients have been
described elsewhere [28]. All patients underwent surgery
for primary tumor resection during which hepatic biop-
sies were also taken. Treated metastases samples were
o b t a i n e df r o mp a t i e n t sw h ow e r ed i a g n o s e dw i t hu n r e -
sectable hepatic metastases and had received CPT-11-
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metastasis resection.
Results
Characterization of the SN38 resistant HCT116 clones
To obtain SN38 resistant clones, we exposed the colon
adenocarcinoma cell line HCT116 to increasing concen-
trations of SN38 (Figure 1A). All five resistant clones
grew slower than the sensitive HCT116-s clone and
consequently their doubling times were 1.2- to 2.1-fold
higher than in HCT116-s cells (Figure 1B). The resistant
clones showed different in vitro level of resistance to
SN38 as indicated by the 6- to 56- fold increase of their
IC50 value (determined by SRB assay) in comparison to
the sensitive HCT116-s cell line (Figure 1B). We have
already shown for HCT116-SN50, that high level of
resistance to SN38 is associated with over-expression of
the ABCG2 efflux pump [7]. This finding was confirmed
in the HCT116-A2 clone which displayed a comparable
high level of resistance to SN38 (Figure 1C). Conversely,
the three other resistant clones did not express ABCG2,
suggesting that these clones have developed different
drug resistant mechanism. To exclude other efflux
mechanisms, the expression of two other efflux proteins
known to transport camptothecin derivatives, Pgp and
MRP1, was assessed by western blotting. Compared to
the MCF7-R positive control, none of the clones dis-
played any detectable amount of PgP or MRP1 (Addi-
tional file 1, Figure S1). We also evaluated by western
blotting the expression of Topoisomerase I (TOP1),
which is often involved in resistance to camptothecin
derivatives. However, its expression (Figure 1C) did not
vary significantly in SN38 sensitive and resistant
HCT116 cells.
Resistant HCT116 cell lines contain novel TOP1 mutations
We previously partially sequenced the TOP1 gene of the
HCT116-s and the HCT116-SN6 cells, and did not find
any of the frequently reported mutations leading to
camptothecin resistance (p.F361, p.G363, p.R364, p.
G503, p.D533, p.G717, p.N722, p.Y723 and p.T729) [22]
in both cell lines. However, since new mutations have
been recently identified [14], we sequenced the entire
TOP1 cDNA of the sensitive and the resistant HCT116
clones. In HCT116-SN6, HCT116-C8, HCT116-G7 cells
(moderately resistant clones) we found two heterozygous
TOP1 point mutations that resulted in missense muta-
tions at position 621 and 710 of the protein. Both muta-
tions were transitions (G®Aa n dA ®G) that caused
Arginine to Histidine (p.R621H) and Glutamate to Gly-
cine (p.E710G) substitutions (Figure 2A). These two
residues interact together via a salt bridge and form part
of the interface between helices 17 and 19 (Figure 2B).
Both mutations may affect this interaction by two
mechanisms. First, the salt bridge is abolished by p.
E710G mutation and, since Histidine is only slightly
protonated at neutral pH, destabilized by p.R621H sub-
stitution. Second, both mutations may also affect the
packing of the two helices since they introduce a residue
with a shorter side chain. In conclusion, both mutations
either present together or alone, may destabilize the
interaction between helices 17 and 19 of the enzyme.
However, if the two mutations are located on the same
allele, the cell will express both a wild type and a
mutated form of the TOP1 protein. We thus cloned the
TOP1 region, which contains the p.R621H and p.E710G
mutations, from HCT116-SN6 cDNA and eight indivi-
dual clones were sequenced. The p.E710G mutation was
present in seven clones and the p.R621H only in one. In
conclusion, HCT116-SN6, HCT116-C8, HCT116-G7
cells contain two new TOP1 mutations which are het-
erozygous and located on different alleles, indicating
that these three cell lines only express mutated forms of
TOP1. The presence of both mutations in these cell
lines was confirmed by HRM curve analysis, a powerful
method for genotyping single nucleotide mutations that
is based on the detection of small differences in the
PCR dissociation curves. The subtractive fluorescent dif-
ference plots of wild type and mutated TOP1 DNA
allowed a clear discrimination between the homozygous
(HCT116-s) and heterozygous (HCT116-SN6, HCT116-
C8, HCT116-G7) cDNA samples (Figure 2C). These
results were obtained using TOP1 primers that surround
the p.R621H and p.E710G mutations.
On the other hand, the highly resistant clones
HCT116-SN50 and HCT116-A2, which over-express
ABCG2, both contained a homozygous mutation (C®A
transversion), which resulted in a Leucine to Isoleucine
substitution at position 617 of the TOP1 protein (Figure
2A). This mutation is located in helix 17 just one turn
before the p.R621H mutation found in the moderately
resistant clones. Despite its conservative nature, this
mutation could also affect the packing of helix 17 and
19 (Figure 2B).
Trapping of DNA cleavage complexes is reduced in SN38
resistant HCT116 cells
In a previous study, we found that in HCT116-s and
HCT116-SN6 cells, which show similar levels of TOP1
expression, TOP1 had comparable intrinsic catalytic
activity by performing a TOP1-mediated DNA relaxa-
tion assay using nuclear extracts [22]. Therefore, since
SN38 resistance seems not to be associated with
changes in TOP1 expression and catalytic activity, we
assessed whether the TOP1 mutations were functionally
relevant by measuring TOP1 cleavage complexes with
the ICE bioassay in SN38 resistant and sensitive
HCT116 cells treated or not with 1 μMS N 3 8f o r1
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were strongly induced in HCT116-s cells, whereas all
the resistant clones showed much weaker induction (up
to 90% lower) whatever the concentration of DNA used
(Figure 3A and 3B). This result indicates that trapping
of cleavage complexes by CPT-11 is decreased in the
resistant cell lines, possibly due to a lower sensitivity of
mutant TOP1 to CPT-11 activity.
DNA double strand break formation is reduced in SN38
resistant HCT116 cells
The conversion of irreversible TOP1 cleavage complexes
leads to DNA cleavage and double-strand break (DSB)
formation. Given the strong decrease of CPT-11-DNA-
TOP1 cleavage complexes observed in the resistant cell
lines, we quantified DSB formation in SN38 sensitive
and resistant HCT116 cells, treated or not with 0.5 μM
SN38 for 20 hours, by following phosphorylation of
H2AX [5] by immunofluorescence (Figure 4A) and
fluorescence-activated cell sorting (Figure 4B). In both
experiments we observed a decrease in H2AX phos-
phorylation (gamma-H2AX) in SN38 resistant cells. To
compare these results, we quantified the percentage of
cells with strong H2AX phosphorylation (i.e., nucleus
entirely stained for IF or fluorescence intensity >10
2 for
FACS experiments). By IF, the percentage of strongly
gamma-H2AX-positive cells decreased from 36% in
HCT116-s cells to 23% in HCT116-SN6 (moderately
resistant clone) and to 6 and 5% in HCT116-A2 and
HCT116-SN50 (highly resistant clones) (Figure 4A).
FACS quantification confirmed these results (Figure 4B).
The percentage of strongly gamma-H2AX-s positive
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Figure 2 New TOP1 mutations: A) The heterozygous mutations p.R621H and p.E710G in HCT116-SN6, HCT116-C8, HCT116-G7 cells and the
homozygous mutation p.L617I in HCT116-SN50 and HCT116-A2 cells were identified by sequencing of TOP1. B) Co-crystal structure of the 70Kd
C-terminal portion of human TOP1 covalently linked to DNA and Topotecan (Protein Data Bank entry 1K4T). The three new TOP1 mutations are
located in the core subdomain III (p.R621H and p.L617I) and in the linker domain (p.E710G). The figure was generated using PyMol [38] and
PovRay software [39] C) p.R621H and p.E710G TOP1 mutations were detected by HRM analysis in the SN38 resistant cell lines (HCT116-SN6, -C8,
-G7), but not in the sensitive HCT116-s clone. The melting profile of HCT116-s was chosen as baseline and the relative differences in the melting
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and 7.5% in HCT116-SN6, HCT116-C8 and HCT116-
G7 cells, respectively, and to 2.4% and 1.3% in the highly
resistant HCT116-A2 and HCT116-SN50 clones. To
avoid the impact of repair processes on DSB quantifica-
tion, the same FACS experiments were performed after
a short exposure to SN38 (5 μM, 1 h). We showed that
the phosphorylation of H2AX is also reduced in the
resistant clones in the similar ratio (50 to 70%
decreases) than after SN38 long exposure (Additional
file 2, Figure S1). These results demonstrate that DSB
formation is reduced in SN38 resistant cells following
incubation with SN38, presumably due to the strong
decrease in TOP1 cleavage complex formation in these
cells (Figure 3).
TOP1 mutations decrease SN38-induced replication fork
asymmetry
Since the primary cytotoxic mechanism of CPT-11 or
SN38 in dividing cells is due to collision between trapped
TOP1 cleavage complexes and moving DNA replication
forks, and TOP1 depleted cells display an increase in forks
stalling without any treatment [29,30], we asked whether
TOP1 mutations in HCT116 resistant cells could influence
DNA fork progression (in particular stalling or pausing).
We used DNA combing to analyze the progression of sis-
ter replication forks in individual DNA fibers from the five
SN38 resistant clones and the sensitive HCT116-s cells
before and after SN38 treatment. Cells were successively
pulse-labeled with IdU (5-iododeoxyuridine) and CldU (5-
chlorodeoxyuridine) and the distance covered by right-
moving and left-moving sister replication forks during the
CldU pulse was determined. Two types of replication sig-
nal could be observed: symmetric (equal length of CldU
green tracks) and asymmetric labeling (Figure 5A), indicat-
ing that replication forks paused or stalled more fre-
quently. In untreated HCT116-s cells, sister forks
progressed at a similar rate from a given origin and gener-
ated symmetrical patterns with all the values included in
less than 25% length differences (Figure 5B). Following
treatment with SN38, 50% of the patterns detected in
HCT116-s cells were asymmetrical, indicating that the
forks stalled more often than in untreated cells probably
because of DNA double strand break formation. Analysis
of the ratio between the longest and the shortest CldU sig-
nals for each pair of sister replication forks revealed a 4-
fold increase in fork asymmetry in HCT116-s cells follow-
ing treatment with SN38 in comparison to untreated cells
(% of asymmetry median = 48%, p < 0.0001) (Figure 5C).
Conversely, no increase in forks asymmetry was observed
after SN38 treatment in the SN38 resistant clones
HCT116-SN50, -A2 and -G7, and only a weak increase in
HCT116-SN6 and -C8 cells. In the absence of drug, the
five resistant clones showed percentage of fork asymmetry
comparable to those of untreated HCT116-s cells (percen-
tages of asymmetry median from 11% for HCT116-s to
15% for HCT116-A2) (Figure 5C). This result indicates
that, differently from TOP1 depletion, the TOP1 muta-
tions identified in the five resistant HCT116 clones have
no impact on replication fork progression when cells are
untreated [30]. Moreover, the weaker effect of SN38 on
replication fork asymmetry in SN38 resistant clones could
be linked to the reduced formation of cleavage complexes
and DNA DSB in these cells.
TOP1 mutations decrease SN38-induced cell cycle
perturbations
Since G2 phase cell cycle arrest is known to be a cellular
response to DNA damage, we examined the cell cycle
distribution of SN38 sensitive and resistant HCT116
cells following incubation with 20 nM of SN38 for 24
hours. As previously reported, SN38 treatment of
HCT116-s cells resulted in strong accumulation of cells
in G2/M phase (from 18% to 60%) and in a decrease in
the proportion of cells in G0/G1 phase (from 41% to
6%) (Figure 6A-6B). These SN38-induced cell cycle per-
turbations were less pronounced in the five SN38
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Figure 3 CPT-11-induced TOP1-DNA complexes:A )T O P 1 - D N A
cleavage complexes measured using the ImmunoComplex of
Enzyme (ICE) assay in nuclear extracts (two concentrations were
used) of SN38 sensitive and resistant HCT116 cells following
treatment with SN38 (1 μM, 1 h). B) Quantification of TOP1-DNA
complexes using Image J Software. The relative intensity of the
immune complexes in SN38-treated cells was normalized to that of
untreated cells. Vertical bars indicate the SD of three independent
experiments. p-values less than 0.05 were considered statistically
significant.
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Page 7 of 13resistant cell lines as their cell cycle profiles were similar
before and after SN38 treatment (Figure 6A-6B). In the
least resistant clone, HCT116-SN6, accumulation in G2/
M phase did not go beyond 38% (from 18% in untreated
cells) and was only 20% and 23% (from 12% in
untreated cells) in the case of the highly resistant clones
HCT116-SN50 and HCT116-A2 (Figure 6B). Together
these results show that the three identified TOP1 muta-
tions decrease the formation of irreversible SN38-TOP1-
DNA cleavage complexes, double-strand breaks and
replication fork collisions. This leads to a reduction of
the drug (CPT-11 or SN38) cytotoxicity, as shown by
the higher IC50 and the lower effect on cell cycle distri-
bution in all the resistant cell lines.
The p.R621H, p.L617I and p.E710G TOP1 mutations are
not detectable in tissue samples from colorectal cancer
patients
F i n a l l yw ei n v e s t i g a t e dw hether these three new TOP1
mutations were present also in biopsies from patients
with colorectal cancer and whether they could be asso-
ciated with their response to CPT-11. We tested 10
primary tumors (3 responders (R) and 7 non-responders
(NR)) and 43 hepatic metastases of which 25 were biop-
sies before treatment (12 R and 13 NR) and 18 after
treatment (12 R and 6 NR) with FOLFIRI (a combina-
tion of leucovorin, 5-FU, and CPT-11) We first per-
formed sequencing by the dideoxynucleotide method
and we did not find the p.R621H, p.L617I or p.E710G
TOP1 mutations. However, since the mutation could be
present in only a small fraction of cancer cells, we then
performed HRM analysis which is known to have a
greater sensitivity than the other currently available
methods [31]. First, to assess the sensitivity of HRM
analysis, serial dilutions of DNA from HCT116-SN6
cells were tested. Each mutation was successfully
detected in up to 10% of the cell population (Figure 7).
However, in spite of this increase in sensitivity, the p.
R621H and p.E710G TOP1 mutations were again not
detected in any of the samples, either before or after
therapy. This indicates that, if these TOP1 mutations are
present, their frequency is below 10% of the entire cell
population and thus impossible to detect with the cur-
rent methods. As in previous studies [19,20], TOP1
A
B
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Figure 4 Assessment of DNA double strand break formation by measuring H2AX phosphorylation in SN38 sensitive and resistant HCT116
cells treated or not with SN38 (0.5 μM SN38 for 20 hours). A) Immunofluorescence: % indicates the number of cells with entirely stained
nucleus. B) Fluorescence-activated cell sorting: % indicates the number of cells with fluorescence intensity >10
2. Data represent the mean ± SD
of at least 3 independent experiments.
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CPT-11-treated patients.
Discussion
In this study, we have characterized five SN38 resistant
clones derived from the HCT116 adenocarcinoma cell
line. They all have a reduced growth rate in comparison
to the sensitive HCT116-s cell line in agreement with
our previous data on one of the SN38 resistant clones
(HCT116-SN6) [22], thus suggesting that their slower
growth rate may account as one of the SN38 resistance
mechanisms. Moreover, we identified three new muta-
tions in the TOP1 gene that could be involved in
the cytotoxicity mechanisms of SN38 and CPT-11.
Specifically, the point mutations p.R621H and p.E710G
are present in moderately resistant clones, whereas the
p.L617I mutation is found in the highly resistant clones
that also over-express ABCG2.
We then investigated the effects of these mutations on
TOP1 and found that, in presence of SN38, both TOP1
cleavage complexes and DSB formation were reduced.
Moreover, DNA combing revealed that SN38-induced
asymmetry in replication forks was decreased. The
asymmetry of sister forks due to the SN38-induced
DNA DSB reported here confirms the CPT-11 (or
SN38) inhibition of origin firing and fork progression
[29]. Indeed, discontinuous fork progression is the con-
sequence of a collision between the replication fork and
C
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Figure 5 Analysis of sister replication-fork progression in SN38 sensitive and resistant HCT116 cells : A) HCT116-s (SN38 sensitive) and
HCT116-SN6, -A2, -SN50, -C8 and -G7 (SN38 resistant) cells were pulse-labeled with IdU and CldU and processed for DNA combing. Replication
forks progress bidirectionally from the origin and incorporate the analogues. A replication fork arrest is detected as an asymmetrical replication
signal. Representative pairs of sister replication forks were assembled from different fields and were centered. Red: IdU and Green: CldU. B)
Scatter plot of the distances covered by right-moving and left-moving sister forks during CldU pulse-labeling in HCT116-s treated or not with
SN38 (each point represents one measurement). The central areas delimited with lines contain sister forks with less than 25% length difference.
The difference of asymmetry is significant p < 0.0001 (Mann Whitney test). C) Box plot of fork asymmetry. Fork asymmetry is expressed as the
ratio between the longest and the shortest distance covered by each pair of sister replication forks during CldU pulse-labeling.
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Page 9 of 13SN38-stabilized TOP1-cleavable complexes resulting in
forks arrest and breakage. Moreover, TOP1 has been
recently shown to be involved in the progression of
replication forks since TOP1 deficient cells display
slower replication fork progression and more pausing or
stalling [30]. All these molecular results confirm that in
resistant cells treated with camptothecin derivatives
there is a decrease of the main mechanism that gener-
ates DNA damage that is TOP1 replication-mediated
DNA DSB.
The decrease of cleavage complexes could be
explained by 1) modified intrinsic catalytic activity of
TOP1, inducing decreased rates of DNA cleavage or
increased rates of re-ligation and leading to diminution
of covalent TOP1-DNA intermediates or 3) reduced affi-
nity of the TOP1-DNA covalent complex for the drug.
The first possibility is not likely as we previously showed
that TOP1 intrinsic catalytic activity is comparable in
the resistant HCT116-SN6 and sensitive HCT116-s cells
[22]. Moreover, we show here that the basal level of
TOP1 cleavage complexes is similar in all the resistant
clones, and they contain an equivalent number of DNA
DSB and display similar fork asymmetry than the sensi-
tive cells, showing that TOP1 activity is not affected in
the untreated resistant clones. Therefore the most prob-
able mechanism is a decrease in TOP1 affinity for CPT-
11 and SN38 due to the mutations. The fact that the
three mutations have apparently the same effect can be
easily explained by their close proximity in the protein.
Indeed, the three residues are packed together, forming
part of the interface between helix 17 of the core subdo-
main III (p.R621H and p.L617I) and helix 19 of the lin-
ker domain (p.E710G). Because of this close proximity,
we can speculate that whatever the mutation, the effect
on the interaction between the core subdomain III and
the linker region will be comparable.
Human TOP1 is arranged in four domains: the NH2-
terminal domain (residues 1-214), the core domain (resi-
dues 215-635), that can be divided in subdomains I, II
and III, the linker domain (residues 636-712) and the
COOH-terminal domain (residues 713-765). The poorly
conserved linker domain, which connects the core and
COOH-terminal domains, is highly flexible [32] and is
dispensable for the catalytic activity [17]. It has been pro-
posed that the lack of a functional linker accounts for the
reduced sensitivity to CPT-11 [33,34]. Among the TOP1
mutations known to be involved in CPT-11 resistance
only one mutation (p.A653P) was found in the linker
domain [18]. The authors suggested that, by increasing
the linker domain flexibility, this mutation may alter the
conformational changes imposed by drug binding, giving
rise to a CPT-11 resistant enzyme. The three mutations
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Figure 6 Effects of SN38 on cell cycle distribution. A) Cell cycle profiles of SN38 sensitive and resistant HCT116 cell lines treated (T, red line)
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comparable mechanism. Indeed, the largest conforma-
tional flexibility of TOP1 is between the core subdomain
III and the linker domain, which can rotate and shift up
to 2.5 Å and 4.6 Å from one to the other. The three
mutations are at positions that are involved in the inter-
action between these two domains but are not disordered
in the structure - except slightly in the case of glutamate
710 [32] and could thus be stabilizing residues. As a con-
sequence their mutation could modulate the structural
flexibility of the linker and the linker fluctuations could
reduce the enzyme affinity for the drug [18,35].
Our knowledge on CPT-11 resistance mechanisms is lar-
gely based on in vitro studies. Indeed, several cell lines
selected for resistance to CPT-11 have been described and
many TOP1 mutations that confer resistance to CPT-11
have been identified in these cells (for instance p.F361S,
p. R364H, p.E418L, p.G503S, p.D533G, p.A653P, and
p.N722S) [17,36,37]. However, such TOP1 mutations
have never been confirmed in clinical samples. This is
also the case of the three new mutations described here.
S i n c ew eh a v es h o w nt h a ta l lt h er e s i s t a n tc e l l sw i t h
TOP1 mutations display reduced growth rate, we could
imagine that in a heterogenic tumoral population, cells
that carry a TOP1 mutation could be overtaken by the
sensitive cells as soon as irinotecan selection pressure
is lifted. This would explain why it is so easy to identify
TOP1 mutations in cellular models, but so difficult to
confirm them in clinical samples.
Conclusions
In this report, we describe three new TOP1 mutations
that are involved in vitro in the development of resis-
tance to camptothecin derivatives. These mutations
seem to affect TOP1/drug interaction by reducing the
affinity or the binding of the drug.
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Figure 7 Assessment of the sensitivity of the HRM analysis. A) p.R621H and B) p.E710G TOP1 mutations detected by HRM in HCT116-s
(wild type) and HCT116-SN6 (mutant) cells and in mixtures of wild type and mutant cells: 1 = 10% mutant, 2 = 20% mutant, 3 = 30% mutant,
4 = 40% mutant, 5 = 50% mutant, 6 = 60% mutant, 7 = 70% mutant, 8 = 80% mutant, 9 = 90% mutant.
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Additional file 1: Figure S1: Immunodetection of efflux pumps Pgp,
MRP1 The multidrug-resistant doxorubicin-selected MCF7-R breast
cancer cell line was used as a positive control for Pgp and MRP1 [7].
Proteins from the extracts (10
5 cells per lane) were electrophoretically
separated on 7.5% SDS-PAGE. Primary antibody used were anti-p-
Glycoprotein clone F4 (Neomarkers, Fremont, CA) and anti-MRP1 (Alexis
Corp, San Diego, CA). Equal loading is shown by b-tubulin (clone tub2.1,
Sigma).
Additional file 2: Figure S1: Assessment of DNA double strand
break formation Assessment of DNA double strand break formation by
measuring H2AX phosphorylation in SN38 sensitive and resistant HCT116
cells treated or not with SN38. Phosphorylated H2AX quantification was
performed by flow cytometry analysis. Cells were plated (1 × 10
5 cells) in
6-well plates and 48 hours later, cells were incubated with 5 μM SN38
for 1 hour. Further FACS experiments were performed as described in
Methods. % indicates the number of cells with fluorescence intensity >2
×1 0
1. Data represent the mean ± SD of at least 3 independent
experiments.
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